CN104136612A - 特异性结合cgrp的核酸 - Google Patents
特异性结合cgrp的核酸 Download PDFInfo
- Publication number
- CN104136612A CN104136612A CN201380009019.6A CN201380009019A CN104136612A CN 104136612 A CN104136612 A CN 104136612A CN 201380009019 A CN201380009019 A CN 201380009019A CN 104136612 A CN104136612 A CN 104136612A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- acid molecule
- seq
- cgrp
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12000105.2 | 2012-01-10 | ||
EP12000105 | 2012-01-10 | ||
PCT/EP2012/000089 WO2012095303A1 (en) | 2011-01-10 | 2012-01-10 | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
EPPCT/EP2012/000089 | 2012-01-10 | ||
PCT/EP2013/000055 WO2013104539A1 (en) | 2012-01-10 | 2013-01-10 | Nucleic acids specifically binding cgrp |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104136612A true CN104136612A (zh) | 2014-11-05 |
Family
ID=48781062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380009019.6A Pending CN104136612A (zh) | 2012-01-10 | 2013-01-10 | 特异性结合cgrp的核酸 |
Country Status (14)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113383079A (zh) * | 2018-11-12 | 2021-09-10 | 阿普塔里恩生物技术股份公司 | Cxcl8结合性核酸 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2802660T (pt) | 2012-01-10 | 2020-04-21 | Aptarion Biotech Ag | Novos ácidos nucleicos que se ligam a c5a |
CN111973740A (zh) | 2014-03-21 | 2020-11-24 | 泰华制药国际有限公司 | 针对降钙素基因相关肽的拮抗剂抗体及其使用方法 |
JP6584868B2 (ja) * | 2015-02-25 | 2019-10-02 | 学校法人 関西大学 | ゲル素材及びその製造方法 |
HK1258385A1 (zh) * | 2015-09-24 | 2019-11-08 | 泰瓦制药国际有限公司 | 预防、治疗和减轻(持续性)创伤後头痛 |
ES2607639B1 (es) | 2015-09-30 | 2018-02-28 | Urquima, S.A | Sal de ácido maleico de un intermedio de silodosina |
SG10201913032TA (en) | 2016-09-23 | 2020-02-27 | Teva Pharmaceuticals Int Gmbh | Treating refractory migraine |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060183700A1 (en) * | 2002-05-06 | 2006-08-17 | Noxxon Pharma Ag | Cgrp binding nucleic acids |
CN101217967A (zh) * | 2005-05-04 | 2008-07-09 | 诺松制药股份公司 | 镜像异构体的新用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
US6682886B1 (en) | 1994-04-28 | 2004-01-27 | Gilead Sciences, Inc. | Bivalent binding molecules of 7 transmembrane G protein-coupled receptors |
EP0777684B1 (en) | 1994-08-16 | 2004-04-28 | Human Genome Sciences, Inc. | Calcitonin receptor |
WO1996038579A1 (en) | 1995-06-02 | 1996-12-05 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to growth factors |
US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
RU2180311C1 (ru) | 2001-07-05 | 2002-03-10 | Мешалкин Георгий Алексеевич | Защитная пробка |
EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
US7629456B2 (en) | 2001-10-26 | 2009-12-08 | Noxxon Pharma Ag | Modified L-nucleic acid |
WO2003070823A2 (en) | 2002-02-20 | 2003-08-28 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
AU2004230927B9 (en) | 2003-04-13 | 2011-12-01 | Enzon Pharmaceuticals, Inc. | Polymeric oligonucleotide prodrugs |
GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
CN1917905B (zh) | 2004-02-09 | 2012-01-04 | 诺松制药股份公司 | 从多糖和多核苷酸生产缀合物的方法 |
DK1732607T3 (da) | 2004-03-23 | 2019-07-22 | Ascendis Pharma Gmbh | Polymer-prodrug med en selvofrende linker |
EP1807092B1 (en) | 2004-11-05 | 2016-09-07 | The Children's Hospital of Philadelphia | Biodegradable linkers for molecular therapies |
MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
US20100062436A1 (en) | 2006-10-31 | 2010-03-11 | Noxxon Pharma Ag | Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule |
CN102906265B (zh) | 2010-04-21 | 2016-08-24 | 诺松制药股份公司 | 脂质结合核酸 |
JP2014504865A (ja) * | 2011-01-10 | 2014-02-27 | ノクソン ファーマ エージー | 標的分子との結合親和性を有する核酸分子およびその生成方法 |
-
2013
- 2013-01-10 HK HK14111873.3A patent/HK1198370A1/xx unknown
- 2013-01-10 US US14/371,210 patent/US9163243B2/en not_active Expired - Fee Related
- 2013-01-10 MX MX2014008456A patent/MX2014008456A/es unknown
- 2013-01-10 AU AU2013209130A patent/AU2013209130A1/en not_active Abandoned
- 2013-01-10 BR BR112014016939A patent/BR112014016939A2/pt not_active IP Right Cessation
- 2013-01-10 WO PCT/EP2013/000055 patent/WO2013104539A1/en active Application Filing
- 2013-01-10 CA CA2860809A patent/CA2860809A1/en not_active Abandoned
- 2013-01-10 JP JP2014551569A patent/JP2015506174A/ja active Pending
- 2013-01-10 RU RU2014132706A patent/RU2014132706A/ru not_active Application Discontinuation
- 2013-01-10 KR KR1020147022328A patent/KR20140111704A/ko not_active Withdrawn
- 2013-01-10 EP EP13700455.2A patent/EP2802659A1/en not_active Withdrawn
- 2013-01-10 CN CN201380009019.6A patent/CN104136612A/zh active Pending
- 2013-01-10 SG SG11201403769YA patent/SG11201403769YA/en unknown
-
2014
- 2014-07-03 IL IL233515A patent/IL233515A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060183700A1 (en) * | 2002-05-06 | 2006-08-17 | Noxxon Pharma Ag | Cgrp binding nucleic acids |
CN101217967A (zh) * | 2005-05-04 | 2008-07-09 | 诺松制药股份公司 | 镜像异构体的新用途 |
Non-Patent Citations (6)
Title |
---|
DENEKAS ET AL.: "Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide", 《BRITISH JOURNAL OF PHARMACOLOGY》 * |
EATON ET AL.: "Post-SELEX Combinatorial Optimization of Aptamers", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
JUHL ET AL.: "Effect of two novel CGRP-binding compounds in a closed cranial window rat model", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 * |
TREVINO ET AL.: "Evolution of functional nucleic acids in the presence of nonheritable backbone heterogeneity", 《PNAS》 * |
VATER ET AL.: "Shot bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach:Tailored-SELEX", 《NUCLEIC ACIDS RESEARCH》 * |
杨晨等: "模拟乳腺癌骨转移微环境中CGRP对成骨细胞OPG和RANKL表达影响", 《中国肿瘤生物治疗杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113383079A (zh) * | 2018-11-12 | 2021-09-10 | 阿普塔里恩生物技术股份公司 | Cxcl8结合性核酸 |
CN113383079B (zh) * | 2018-11-12 | 2024-11-19 | 阿普塔里恩生物技术股份公司 | Cxcl8结合性核酸 |
Also Published As
Publication number | Publication date |
---|---|
RU2014132706A (ru) | 2016-02-27 |
HK1198370A1 (en) | 2015-04-10 |
CA2860809A1 (en) | 2013-07-18 |
KR20140111704A (ko) | 2014-09-19 |
WO2013104539A1 (en) | 2013-07-18 |
SG11201403769YA (en) | 2014-07-30 |
JP2015506174A (ja) | 2015-03-02 |
IL233515A0 (en) | 2014-08-31 |
EP2802659A1 (en) | 2014-11-19 |
US9163243B2 (en) | 2015-10-20 |
US20150031755A1 (en) | 2015-01-29 |
BR112014016939A2 (pt) | 2019-09-24 |
MX2014008456A (es) | 2014-11-25 |
AU2013209130A1 (en) | 2014-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104136612A (zh) | 特异性结合cgrp的核酸 | |
KR102021626B1 (ko) | Ngf에 대한 압타머 및 그의 용도 | |
CN103339258A (zh) | 具有对于靶分子的结合亲和力的核酸分子及产生所述核酸分子的方法 | |
CN101189337A (zh) | 生长素释放肽结合核酸 | |
JP4823067B2 (ja) | 生物活性グレリンに特異的に結合する核酸 | |
CN103555725A (zh) | Sdf-1结合性核酸 | |
CN103958682A (zh) | 结合胰高血糖素的核酸 | |
CN101809154A (zh) | C5a结合核酸 | |
TWI500425B (zh) | 對ngf之適體及其用途 | |
JP4644599B2 (ja) | グレリン結合核酸 | |
EP3065744B1 (en) | A ccl2 antagonist for use in treating proteinuria | |
WO2013082515A2 (en) | Nucleic acid aptamers directed to surface receptors and methods of use | |
ES2368041T3 (es) | Ácidos nucleicos de unión a ghrelina. | |
HK1130506B (en) | Compounds and methods for peptide ribonucleic acid condensate particles for rna therapeutics | |
HK1184699B (en) | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141105 |